Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs 1,319

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,319 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 4 of 28

  1. ACE-LY-106

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 1 other active

    1 trial

  2. ACR-2316

    Acrivon Therapeutics

    Specific Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  3. ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195

    Actinium Pharmaceuticals

    Leukemia

    phase 1 mab completed

    1 trial

  4. ACTR T Cell Product

    Cogent Biosciences

    Solid Tumor

    phase 1 mab terminated

    1 trial

  5. ACTR087

    Cogent Biosciences

    Lymphoma

    phase 1 mab completed

    1 trial

  6. ACTR707

    Cogent Biosciences

    Lymphoma

    phase 1 mab terminated

    1 trial

  7. ADCLEC.syn1 CAR T cells

    Takeda

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  8. ADCT-301

    ADC Therapeutics SA

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  9. ADCT-301

    ADC Therapeutics SA

    Head and Neck Cancer Squamous Cell Carcinoma

    phase 1 small molecule terminated

    1 trial

  10. ADCT-402

    ADC Therapeutics SA

    Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  11. ADCT-402

    ADC Therapeutics SA

    Non-Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  12. ADCT-402-105

    ADC Therapeutics SA

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  13. ADCT-502

    ADC Therapeutics SA

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  14. ADCT-601

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule terminated

    2 trials

  15. ADCT-901

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  16. ADO-01-24

    Lacuna Pharma Pty Ltd

    Patients suffering from cancer without further treatment options.

    phase 1 other active

    1 trial

  17. AG-636

    Agios Netherlands B.V.

    Lymphoma

    phase 1 small molecule terminated

    1 trial

  18. AG120-221-C-001

    The George Institute

    Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    phase 1 other active

    1 trial

  19. AG881

    Agios Netherlands B.V.

    Acute Myeloid Leukemia (AML)

    phase 1 small molecule completed

    1 trial

  20. ALLO-316

    Allogene Therapeutics

    Advanced/Metastatic Clear Cell Renal Cell Carcinoma

    phase 1 gene therapy active

    1 trial

  21. ALLO-501

    Allogene Therapeutics

    Relapsed/Refractory Large B Cell Lymphoma

    phase 1 gene therapy completed

    1 trial

  22. ALN-BCAT

    Alnylam Netherlands B.V.

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  23. ALN-VSP02

    Alnylam Netherlands B.V.

    Solid Tumors

    phase 1 small molecule completed

    2 trials

  24. ALX2004

    ALX ONCOLOGY HOLDINGS INC

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 small molecule active

    1 trial

  25. AMBER

    TESARO Bio Netherlands B.V.

    Patients with Advanced Solid Tumors

    phase 1 other active

    1 trial

  26. AMG 509

    BEONE MEDICINES AUS PTY LTD

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  27. AMT-116

    Multitude Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  28. AMT-676

    Multitude Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  29. APHP191116

    Pari Pharma GmbH

    hematologic malignancies ; acute myeloid leukemias

    phase 1 other active

    1 trial

  30. APL-1202 and APL-1501 (Single ascending dose)

    Jian Li

    Bladder Cancer

    phase 1 small molecule active

    1 trial

  31. APR-1051

    Aprea Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  32. APR-246

    Aprea Therapeutics

    Hematologic Neoplasms

    phase 1 small molecule completed

    1 trial

  33. APTO-253

    Aptose Biosciences

    Acute Myelogenous Leukemia in Relapse

    phase 1 small molecule terminated

    1 trial

  34. APVO436

    Aptevo Therapeutics

    Acute Myeloid Leukemia (AML)

    phase 1 small molecule active

    1 trial

  35. ARC-12

    Arcus Biosciences

    Multiple Myeloma, Diffuse large B cell lymphoma (DLBCL), Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Advanced Solid Tumor, Gastrointestinal (GI) cancer, Hematological (heme) cancer, Gynecological (Gyn) cancer, Non-small cell lung cancer (NSCLC), Non-Hodgkin Lymphoma, Gastric Cancer, Cervical Cancer

    phase 1 other active

    1 trial

  36. ARC-20

    Arcus Biosciences

    Solid Tumors, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  37. ARISE with AR

    BRIGHT MINDS BIOSCIENCES INC.

    Pediatric Cancer

    phase 1 other active

    1 trial

  38. ARO-HIF2

    Arrowhead Pharmaceuticals Ireland Limited

    Clear Cell Renal Cell Carcinoma

    phase 1 small molecule completed

    1 trial

  39. ARQ 197

    KYOWA KIRIN AUSTRALIA PTY LTD

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  40. ASTX660

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  41. ASTX727-17

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors

    phase 1 other active

    1 trial

  42. ASTX727-18

    Taiho Pharma Netherlands B.V.

    Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)

    phase 1 other active

    1 trial

  43. ATA3219

    Evidence Based Cataract Study Group

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  44. ATG-010 and ATG-008

    Shanghai Antengene Corporation Limited

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 1 other terminated

    1 trial

  45. ATI-2231

    Aclaris Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  46. ATRA

    United Therapeutics Europe Ltd

    Pancreatic Adenocarcinoma

    phase 1 small molecule completed

    1 trial

  47. AU-011

    Aura Biosciences

    Non-muscle-invasive Bladder Cancer

    phase 1 small molecule active

    1 trial

  48. AVE0005 (aflibercept)

    Regeneron UK Limited

    Colorectal Neoplasms

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,319 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.